Shares of Eli Lilly & Co. LLY rallied 3.26% to $864.90 Monday, on what proved to be an all-around great trading session for ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 71 trades. If we consider the specifics of each ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. Some of the major U.S. indexes began recovering on Wednesday, following the ...

Earlier this week, Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual care companies ...

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Eli Lilly. Also, EPS is estimated to ramp higher this year by +27.4%.

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Eli Lilly has reduced the prices of certain ...